Lilly's Jaypirca wins FDA approval for first-line CLL/SLL treatment
The expanded label moves the BTK inhibitor into front-line use for chronic lymphocytic leukemia and small lymphocytic lymphoma.
Read at scanx.trade →Full coverage · 7 outlets
- scanx.trade · lead
- Fierce PharmaWith FDA approval, Lilly’s BTK drug Jaypirca enters first-line CLL
- Pharmaceutical ExecutiveEMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval
- PR NewswireLilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
- Yahoo FinanceEli Lilly (LLY) Wins EMA Backing For Jaypirca In Chronic Lymphocytic Leukemia
- Mugglehead Investment MagazineEli Lilly and Company wins first-line Jaypirca approval for CLL/SLL
- StreetinsiderFDA approves Lilly's Jaypirca for first-line CLL/SLL treatment